



The Cooper Companies Announces Its Subsidiary CooperVision Has Received FDA Special 510(K) Clearance on Its Avaira Toric Contact Lenses

PLEASANTON, Calif., April 5, 2012 (GLOBE NEWSWIRE) -- The Cooper Companies, Inc. (NYSE:COO) today announced that the U.S. Food and Drug Administration has granted a Special 510(k) clearance for CooperVision's Avaira® Toric two-week silicone hydrogel contact lenses for astigmatism.

CooperVision will re-launch Avaira Toric with shipments available for select distribution beginning in early May 2012.

About The Cooper Companies

The Cooper Companies, Inc. ("Cooper") is a global medical device company publicly traded on the NYSE Euronext (NYSE:COO). Cooper is dedicated to being A Quality of Life Company™ with a focus on delivering shareholder value. Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to crafting a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical focuses on supplying women's health clinicians with market leading products and treatment options to improve the delivery of healthcare to women. Headquartered in Pleasanton, CA, Cooper has over 7,000 employees with products sold in over 100 countries. For more information, please visit www.cooperco.com.

The Cooper Companies, Inc. logo is available at <http://www.globenewswire.com/newsroom/prs/?pkgid=10403>

COO-G

CONTACT: Kim Duncan

Senior Director, Investor Relations

The Cooper Companies, Inc.

ir@cooperco.com



Source: The Cooper Companies, Inc.

News Provided by Acquire Media